OTC · Medical - Pharmaceuticals

BioSyent Inc. (BIOYF) Stock

$10.50 +0.41% OTC: BIOYF Healthcare

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.

Valuation

MetricValue
Price$10.50
Market Cap$120.04M
P/E Ratio18.10
P/B Ratio3.69
P/S Ratio3.65
EPS (TTM)$0.58
52-Week High$12.00
52-Week Low$7.63
Dividend Yield1.52%

Financials & Margins

MetricValue
ROE22.05%
ROA14.46%
ROCE25.13%
Gross Margin74.11%
Operating Margin25.10%
Net Margin19.65%
Debt/Equity0.12
Current Ratio1.89

Annual Financials (USD)

Metric20212022202320242025
Revenue$29.0M$28.0M$32.0M$35.0M$43.0M
Operating Profit$8.0M$7.0M$7.0M$9.0M$11.0M
Net Profit$6.0M$5.0M$6.0M$7.0M$9.0M
EPS$0.49$0.44$0.53$0.64$0.78
Op Margin28.6%25.0%23.6%25.0%26.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$37.0M$40.0M$42.0M$41.0M$49.0M
Total Liabilities$6.0M$7.0M$7.0M$6.0M$8.0M
Cash$18.0M$8.0M$8.0M$12.0M$20.0M
Borrowings$2.0M$1.0M$1.0M$1.0M$1.0M

Latest News

BioSyent to Present at Planet MicroCap Las Vegas GlobeNewswire · Jun 15, 2026 BioSyent Secures Health Canada Nod For Hypothyroidism Oral Solution MT Newswires · May 19, 2026 BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution) GlobeNewswire · May 19, 2026 BioSyent Declares Second Quarter 2026 Dividend GlobeNewswire · May 14, 2026 BioSyent Releases Financial Results for First Quarter 2026 GlobeNewswire · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$5.0M$5.0M$5.0M$9.0M$10.0M
Investing Cash Flow$-5.0M$-11.0M$1.0M$-1.0M$3.0M
Financing Cash Flow$-2.0M$-4.0M$-3.0M$-6.0M$-1.0M
Net Cash Flow$-2.0M$-10.0M$0$4.0M$11.0M
Free Cash Flow$5.0M$4.0M$5.0M$4.0M$10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.04
EV / EBITDA12.72
FCF Yield7.57%
Quick Ratio1.21
Interest Coverage170.06
Return 1Y29.16%
Return 3Y93.93%
Return 5Y—

Ownership

Insiders Held34.86%
Institutions Held4.01%
Institutions Float Held6.15%
Institutional HolderSharesReport Date
Adirondack Retirement Specialists, Inc12023-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ETSTEarth Science Tech, Inc. $0.15 +7.14% 12.20 $43.23M 0.00%
GGBXFGreen Growth Brands Inc. $0.00 — 0.00 $2061 0.00%
GRUSFGrown Rogue International Inc. $0.41 +2.68% -123.21 $102.47M 0.00%
IUGNFImugene Limited $0.10 +0.00% -0.40 $41.60M 0.00%
LOVFFCannara Biotech Inc. $1.33 -3.47% 17.22 $131.11M 0.00%

About BioSyent Inc.

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.

BioSyent Inc. is headquartered in CA.

BioSyent Inc. (BIOYF) stock trades at $10.50 with a market capitalization of $120.04M. The stock is valued at a price-to-earnings (P/E) ratio of 18.10, price-to-book of 3.69, price-to-sales of 3.65. Over the past 52 weeks the stock has ranged between $7.63 and $12.00, and currently trades 12.5% below its 52-week high. It pays a dividend yielding 1.52%.

On profitability, BioSyent Inc. generates a return on equity (ROE) of 22.05% — well above the market average, a sign of a high-quality business, return on capital employed of 25.13%, an operating margin of 25.10%, a net profit margin of 19.65%.

Official website: www.biosyent.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides